Omniscient develops clinical software focused on translating connectomics into routine neurosurgical workflows. The company operates at the intersection of neuroimaging, surgical planning, and decision support, positioning connectomic analysis as a reportable clinical service rather than a research-only output.

Its core product, Quicktome, is an FDA-cleared radiological image-processing platform that analyzes existing MRI data, including diffusion imaging and resting-state fMRI, to generate patient-specific brain network maps. The system integrates multimodal imaging to infer functional and structural connectivity, producing clinician-reviewed outputs designed to complement anatomical imaging and traditional functional mapping.

Omniscient’s software is used primarily in preoperative planning for neurosurgical cases such as brain tumors and epilepsy, where preserving functional networks is critical. Deployments are situated in hospital neurosurgery and radiology settings, with usage framed as decision support rather than intraoperative replacement. Within the broader neuroimaging ecosystem, the company is positioned as a platform layer enabling network-level analysis on top of standard clinical MRI workflows.